BRNS · Barinthus Biotherapeutics plc. · Metrics
Market Cap
$30.23M
Shares
40.85M
BRNS metrics
55 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$0.74
Market cap
$30.23M
Price action
20 metricsPrice change (1W)
-3.3%
Price change (30D)
+25.2%
Price change (3M)
+2.2%
Price change (6M)
+31.0%
Price change (YTD)
+5.7%
Price change (1Y)
-39.1%
Trailing year
Price change (5Y)
-95.1%
52-week high
$1.58
52-week low
$0.54
Change from 52-week high
-53.2%
Change from 52-week low
+37.1%
Annualized volatility
78.8%
Annualized volatility (3M)
76.1%
Beta
0.9
RSI (14D)
60.2
Price vs SMA 50
+17.6%
Price vs SMA 200
+12.4%
Avg volume (3M)
57,868
Relative volume
6.5
Average dollar volume
$39,001
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
40.85M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.5
reciprocal yield 188.8%
FCF yield
-87.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-138.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-05-07
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$43.73M
Net income (TTM)
−$41.76M
Trailing 12 months
Diluted EPS (TTM)
$-1.03
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-73.2%
Return on assets
-51.0%
Debt / equity
—
Current ratio
5.5
EBITDA (TTM)
−$40.24M
Free cash flow (TTM)
−$26.43M
Quick ratio
5.5
Interest coverage
-825.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$59.30M
Total assets
$81.89M
Total debt
$159,000
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$26.43M
Capital expenditures (TTM)
$0
R&D (TTM)
$16.84M
SG&A (TTM)
—
Stock compensation (TTM)
$1.27M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
15
13F filer change QoQ
+1
Institutional ownership
22.5%
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
58 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—